Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab

Journal of Clinical Oncology

Volumn 34, Issue 13, 2016, Pages 1510-1517

  Hodi, F Stephen ^a   Hwu, Wen Jen ^b   Kefford, Richard ^d   Weber, Jeffrey S ^f   Daud, Adil ^h   Hamid, Omid ⁱ   Patnaik, Amita ^c   Ribas, Antoni ^j   Robert, Caroline ^k   Gangadhar, Tara C ^l   Joshua, Anthony M ^m   Hersey, Peter ^e   Dronca, Roxana ⁿ   Joseph, Richard ^g   Hille, Darcy ^o   Xue, Dahai ^o   Li, Xiaoyun Nicole ^o   Kang, S Peter ^o   Ebbinghaus, Scot ^o   Perrone, Andrea ^o   Wolchok, Jedd D ^p   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c South Texas Accelerated Research Therapeutics   (United States)

^d MACQUARIE UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ MAYO CLINIC   (United States)

^o MERCK RESEARCH LABORATORIES   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DEFECT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; YOUNG ADULT; CASE REPORT; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 84968779639     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.0391     Document Type: Article

References (22)

1. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
2. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
3. O'Day S.J., Maio M, Chiarion-Sileni V, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21: 1712-1717, 2010
4. Nishino M, Jagannathan JP, Krajewski K.M., et al: Personalized tumor response assessment in the era of molecular medicine: Cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198: 737-745, 2012
5. Nishino M, Giobbie-Hurder A, Gargano M., et al: Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin Cancer Res 19:3936-3943, 2013
6. Therasse P, Arbuck SG, Eisenhauer E.A., et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
7. Eisenhauer EA, Therasse P, Bogaerts J., et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
8. Lynch TJ, Bondarenko I, Luft A., et al: Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046-2054, 2012
9. Nishino M, Gargano M, Suda M., et al: Optimizing immune-related tumor response assessment: Does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2: 17, 2014
10. Agata Y, Kawasaki A, Nishimura H., et al: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-772, 1996
11. Barber DL, Wherry EJ, Masopust D, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687, 2006
12. Keir ME, Butte MJ, Freeman G.J., et al: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008
13. Karwacz K, Bricogne C, MacDonald D., et al: PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med 3:581-592, 2011
14. Dong H, Strome SE, Salomao D.R., et al: Tumor associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793-800, 2002
15. Hamid O, Robert C, Daud A., et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
16. Robert C, Ribas A, Wolchok J.D., et al: Anti programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
17. Ribas A, Wolchok JD, Robert C, et al: Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (pembro, MK-3475) in 411 patients (pts) with melanoma (MEL). Pigment Cell Melanoma Res 27:1222-1223, 2014 (abstr)
18. Daud A, Ribas A, Robert C., et al: Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33: 2015 (suppl; abstr 9005)
19. Bohnsack O, Hoos A, Ludajic K: Adaptation of the immune related response criteria: irRECIST. Ann Oncol 25:iv369, 2014 (suppl 4; abstr 1070P)
20. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
21. Herbst RS, Soria J-C, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014
22. Chiou VL, Burotto M: Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541-3543, 2015